NuVasive (NUVA +5.7%) gets a bump from some positive comments out of JMP Securities today, saying that after surveying top hospital executives, it believes that growth in spine surgery and back pain surgery is exceeding expectations. The firm notes that NUVA has little exposure to Europe, and ups its price target to $25 from $21.
NuVasive (NUVA +5.7%) gets a bump from some positive comments out of JMP Securities today,...
From other sites
at CNBC.com (Oct 4, 2012)
at CNBC.com (Oct 3, 2012)
at CNBC.com (Jun 28, 2012)
at CNBC.com (Jun 23, 2010)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs